Reginald Heywood1, Alexandra L McCarthy2, Tina L Skinner3. 1. School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Australia. reginald.heywood@uq.net.au. 2. School of Nursing, University of Auckland, Auckland, New Zealand. 3. School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Australia.
Abstract
GOALS OF WORK: The beneficial effects of exercise in cancer patients are reasonably well-established, although research in this field has predominantly investigated cancer patients in the earlier stages of disease. However, the most recent evidence surrounding exercise interventions in advanced cancer populations has yet to be systematically evaluated. This review critically analyses the safety and feasibility of exercise interventions in patients with advanced cancer. METHODS: All randomised, non-randomised and prospective observational trials of exercise training interventions in patients with advanced cancer were included. 'Safety' was defined as the number and severity of reported adverse events during exercise training. 'Feasibility' was determined by participant adherence, attendance and/or study completion rates. RESULTS: A total of 25 studies involving 1088 patients were included: 16 randomised controlled and nine prospective observational cohort trials. Seven studies included advanced lung cancer patients exclusively, while eight involved patients with various cancer diagnoses. Aerobic exercise was investigated in five studies, resistance training in two studies and combination training (aerobic and resistance) in 14 studies. Six minor adverse events were reported due to exercise. All of these were musculoskeletal in nature, resulting in two participants' withdrawal from the study. Exercise adherence ranged from 65 to 89% but was only described in nine studies. Attendance at each exercise session was described in a further nine studies, ranging from 59 to 100%. CONCLUSIONS: Implementation of exercise interventions appears to be safe and feasible in advanced cancer clinical practice, although targeted studies are required to determine the optimal exercise dose for specific cancer diagnoses.
GOALS OF WORK: The beneficial effects of exercise in cancerpatients are reasonably well-established, although research in this field has predominantly investigated cancerpatients in the earlier stages of disease. However, the most recent evidence surrounding exercise interventions in advanced cancer populations has yet to be systematically evaluated. This review critically analyses the safety and feasibility of exercise interventions in patients with advanced cancer. METHODS: All randomised, non-randomised and prospective observational trials of exercise training interventions in patients with advanced cancer were included. 'Safety' was defined as the number and severity of reported adverse events during exercise training. 'Feasibility' was determined by participant adherence, attendance and/or study completion rates. RESULTS: A total of 25 studies involving 1088 patients were included: 16 randomised controlled and nine prospective observational cohort trials. Seven studies included advanced lung cancerpatients exclusively, while eight involved patients with various cancer diagnoses. Aerobic exercise was investigated in five studies, resistance training in two studies and combination training (aerobic and resistance) in 14 studies. Six minor adverse events were reported due to exercise. All of these were musculoskeletal in nature, resulting in two participants' withdrawal from the study. Exercise adherence ranged from 65 to 89% but was only described in nine studies. Attendance at each exercise session was described in a further nine studies, ranging from 59 to 100%. CONCLUSIONS: Implementation of exercise interventions appears to be safe and feasible in advanced cancer clinical practice, although targeted studies are required to determine the optimal exercise dose for specific cancer diagnoses.
Authors: Morten Quist; Mikael Rørth; Seppo Langer; Lee W Jones; Jørgen H Laursen; Helle Pappot; Karl Bang Christensen; Lis Adamsen Journal: Lung Cancer Date: 2011-08-03 Impact factor: 5.705
Authors: Lis Adamsen; Morten Quist; Julie Midtgaard; Christina Andersen; Tom Møller; Lasse Knutsen; Anders Tveterås; Mikael Rorth Journal: Support Care Cancer Date: 2005-08-12 Impact factor: 3.603
Authors: Jennifer M Hootman; Carol A Macera; Barbara E Ainsworth; Cheryl L Addy; Malissa Martin; Steven N Blair Journal: Med Sci Sports Exerc Date: 2002-05 Impact factor: 5.411
Authors: Morten Quist; Lis Adamsen; Mikael Rørth; Jørgen H Laursen; Karl B Christensen; Seppo W Langer Journal: Integr Cancer Ther Date: 2015-03-22 Impact factor: 3.279
Authors: D Jastrzębski; M Maksymiak; S Kostorz; B Bezubka; I Osmanska; T Młynczak; A Rutkowska; Z Baczek; D Ziora; J Kozielski Journal: Adv Exp Med Biol Date: 2015 Impact factor: 2.622
Authors: R Crevenna; M Schmidinger; M Keilani; M Nuhr; V Fialka-Moser; G Zettinig; M Quittan Journal: Support Care Cancer Date: 2002-11-01 Impact factor: 3.603
Authors: Harald Rief; Michael Akbar; Monika Keller; Georg Omlor; Thomas Welzel; Thomas Bruckner; Stefan Rieken; Matthias F Häfner; Ingmar Schlampp; Alexandros Gioules; Jürgen Debus Journal: Radiat Oncol Date: 2014-07-07 Impact factor: 3.481
Authors: Caroline S Kampshoff; Mai J M Chinapaw; Johannes Brug; Jos W R Twisk; Goof Schep; Marten R Nijziel; Willem van Mechelen; Laurien M Buffart Journal: BMC Med Date: 2015-10-29 Impact factor: 8.775
Authors: Lara Edbrooke; Linda Denehy; Catherine L Granger; Suzanne Kapp; Sanchia Aranda Journal: Support Care Cancer Date: 2019-04-13 Impact factor: 3.603
Authors: Amy M Dennett; Bernadette Zappa; Rachel Wong; Stephen B Ting; Kimberley Williams; Casey L Peiris Journal: Support Care Cancer Date: 2021-05-08 Impact factor: 3.603
Authors: Brett C Bade; J Madison Hyer; Benjamin T Bevill; Alex Pastis; Alana M Rojewski; Benjamin A Toll; Gerard A Silvestri Journal: Integr Cancer Ther Date: 2018-06-14 Impact factor: 3.279